FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969704902> ?p ?o ?g. }

• W2969704902 endingPage "106" @default.
• W2969704902 startingPage "97" @default.
• W2969704902 abstract "BackgroundDual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used. The objective of this study was to fully describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK inhibitor combination encorafenib+binimetinib.Patients and methodsPatients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma were randomised to receive encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, encorafenib 300 mg once daily or vemurafenib 960 mg twice daily. Adverse events that represent known effects of available BRAFi and/or MEKi were evaluated.ResultsThe safety population included a total of 570 patients (encorafenib+binimetinib = 192; encorafenib = 192; vemurafenib = 186). Median duration of exposure was longer with encorafenib+binimetinib (51 weeks) than with encorafenib (31 weeks) or vemurafenib (27 weeks). Common BRAFi/MEKi toxicities with encorafenib+binimetinib were generally manageable, reversible and infrequently associated with discontinuation. Pyrexia was less frequent with encorafenib+binimetinib (18%) and encorafenib (16%) than with vemurafenib (30%) and occurred later in the course of therapy with encorafenib+binimetinib (median time to first onset: 85 days versus 2.5 days and 19 days, respectively). The incidence of photosensitivity was lower with encorafenib+binimetinib (5%) and encorafenib (4%) than with vemurafenib (30%). The incidence of serous retinopathy was higher with encorafenib+binimetinib (20%) than with encorafenib (2%) or vemurafenib (2%), but no patients discontinued encorafenib+binimetinib because of this event.ConclusionEncorafenib+binimetinib is generally well tolerated and has a low discontinuation rate in patients with BRAFV600-mutant melanoma, with a distinct safety profile as compared with other anti-BRAF/MEK targeted therapies.Trial registrationClinicalTrials.gov (Identifier: NCT01909453) and with EudraCT (number 2013-001176-38)." @default.
• W2969704902 created "2019-08-29" @default.
• W2969704902 creator A5001548963 @default.
• W2969704902 creator A5001893646 @default.
• W2969704902 creator A5006048202 @default.
• W2969704902 creator A5009056091 @default.
• W2969704902 creator A5010492722 @default.
• W2969704902 creator A5011197831 @default.
• W2969704902 creator A5015081105 @default.
• W2969704902 creator A5023174631 @default.
• W2969704902 creator A5024976681 @default.
• W2969704902 creator A5029398339 @default.
• W2969704902 creator A5034365278 @default.
• W2969704902 creator A5041301470 @default.
• W2969704902 creator A5049703322 @default.
• W2969704902 creator A5055627811 @default.
• W2969704902 creator A5056132643 @default.
• W2969704902 creator A5066911633 @default.
• W2969704902 creator A5077331259 @default.
• W2969704902 creator A5089297467 @default.
• W2969704902 creator A5090633646 @default.
• W2969704902 date "2019-09-01" @default.
• W2969704902 modified "2023-10-15" @default.
• W2969704902 title "Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management" @default.
• W2969704902 cites W1965370740 @default.
• W2969704902 cites W1971947883 @default.
• W2969704902 cites W2049979602 @default.
• W2969704902 cites W2093550507 @default.
• W2969704902 cites W2096387850 @default.
• W2969704902 cites W2110478149 @default.
• W2969704902 cites W2115562945 @default.
• W2969704902 cites W2121545342 @default.
• W2969704902 cites W2154841567 @default.
• W2969704902 cites W2155111125 @default.
• W2969704902 cites W2160766792 @default.
• W2969704902 cites W2163188200 @default.
• W2969704902 cites W2170065082 @default.
• W2969704902 cites W2320842203 @default.
• W2969704902 cites W2467209382 @default.
• W2969704902 cites W2491982852 @default.
• W2969704902 cites W2509999533 @default.
• W2969704902 cites W2605630889 @default.
• W2969704902 cites W2614470022 @default.
• W2969704902 cites W2624834472 @default.
• W2969704902 cites W2752016319 @default.
• W2969704902 cites W2793817570 @default.
• W2969704902 cites W2891205725 @default.
• W2969704902 doi "https://doi.org/10.1016/j.ejca.2019.07.016" @default.
• W2969704902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31437754" @default.
• W2969704902 hasPublicationYear "2019" @default.
• W2969704902 type Work @default.
• W2969704902 sameAs 2969704902 @default.
• W2969704902 citedByCount "51" @default.
• W2969704902 countsByYear W29697049022019 @default.
• W2969704902 countsByYear W29697049022020 @default.
• W2969704902 countsByYear W29697049022021 @default.
• W2969704902 countsByYear W29697049022022 @default.
• W2969704902 countsByYear W29697049022023 @default.
• W2969704902 crossrefType "journal-article" @default.
• W2969704902 hasAuthorship W2969704902A5001548963 @default.
• W2969704902 hasAuthorship W2969704902A5001893646 @default.
• W2969704902 hasAuthorship W2969704902A5006048202 @default.
• W2969704902 hasAuthorship W2969704902A5009056091 @default.
• W2969704902 hasAuthorship W2969704902A5010492722 @default.
• W2969704902 hasAuthorship W2969704902A5011197831 @default.
• W2969704902 hasAuthorship W2969704902A5015081105 @default.
• W2969704902 hasAuthorship W2969704902A5023174631 @default.
• W2969704902 hasAuthorship W2969704902A5024976681 @default.
• W2969704902 hasAuthorship W2969704902A5029398339 @default.
• W2969704902 hasAuthorship W2969704902A5034365278 @default.
• W2969704902 hasAuthorship W2969704902A5041301470 @default.
• W2969704902 hasAuthorship W2969704902A5049703322 @default.
• W2969704902 hasAuthorship W2969704902A5055627811 @default.
• W2969704902 hasAuthorship W2969704902A5056132643 @default.
• W2969704902 hasAuthorship W2969704902A5066911633 @default.
• W2969704902 hasAuthorship W2969704902A5077331259 @default.
• W2969704902 hasAuthorship W2969704902A5089297467 @default.
• W2969704902 hasAuthorship W2969704902A5090633646 @default.
• W2969704902 hasBestOaLocation W29697049021 @default.
• W2969704902 hasConcept C2776131300 @default.
• W2969704902 hasConcept C2777658100 @default.
• W2969704902 hasConcept C2994587330 @default.
• W2969704902 hasConcept C502942594 @default.
• W2969704902 hasConcept C71924100 @default.
• W2969704902 hasConceptScore W2969704902C2776131300 @default.
• W2969704902 hasConceptScore W2969704902C2777658100 @default.
• W2969704902 hasConceptScore W2969704902C2994587330 @default.
• W2969704902 hasConceptScore W2969704902C502942594 @default.
• W2969704902 hasConceptScore W2969704902C71924100 @default.
• W2969704902 hasFunder F4320306521 @default.
• W2969704902 hasFunder F4320307105 @default.
• W2969704902 hasFunder F4320307115 @default.
• W2969704902 hasFunder F4320307762 @default.
• W2969704902 hasFunder F4320307776 @default.
• W2969704902 hasFunder F4320307778 @default.
• W2969704902 hasFunder F4320307779 @default.
• W2969704902 hasFunder F4320309577 @default.
• W2969704902 hasFunder F4320310030 @default.

• next